NPCE (NeuroPace) YoY EPS Growth: 30.77% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NPCE NeuroPace Inc NPCE
70 GF Score
Price $14.16
GF Value $12.60
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is NeuroPace YoY EPS Growth?

NeuroPace NPCE +1.22% 70 YoY EPS Growth is 30.77% as of Jun. 2026. GuruFocus rates NPCE with a GF Score™ of 70/100 and a GF Value™ of $12.60 (Modestly Overvalued). The stock has 3 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. NeuroPace's YoY EPS Growth for the quarter that ended in Jun. 2026 was 30.77%.

NeuroPace's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.18.

NeuroPace YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for NeuroPace's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroPace YoY EPS Growth Chart

NeuroPace Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial -0.18 11.98 33.51 26.77 29.03

NeuroPace Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 42.11 55.56 4.76 30.77
NPCE
70GF Score
NeuroPace Inc NPCE
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroPace YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

NeuroPace's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-0.66--0.93)/ | -0.93 |
=29.03 %

NeuroPace's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.18--0.26)/ | -0.26 |
=30.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 30.77% mean?
NeuroPace (NPCE) has a YoY EPS Growth of 30.77% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for NeuroPace and its competitors.
Is NeuroPace's YoY EPS Growth too high?
NeuroPace's current YoY EPS Growth is 30.77%. Overall, NeuroPace has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's YoY EPS Growth compare to KIDS and VREX?
NeuroPace's YoY EPS Growth of 30.77% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for NeuroPace and its competitors. NeuroPace's current YoY EPS Growth is 30.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.60, compared to a current price of $14.16 — trading 12.4% above its estimated fair value. The current YoY EPS Growth is 30.77%. NeuroPace's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For NeuroPace (NPCE), the current YoY EPS Growth is 30.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroPace (NPCE) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued. The current stock price of $14.16 is trading 12.4% above its estimated GF Value™ of $12.60. GuruFocus considers NeuroPace to be Modestly Overvalued.

Key valuation signals for NPCE:

  • YoY EPS Growth: 30.77%
  • GF Value™: $12.60 vs. price of $14.16 (12.4% above fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroPace Business Description

Address 455 N. Bernardo Avenue, Mountain View, CA, USA, 94043
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
70GF Score

Get the complete analysis for NPCE

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.16
Price
$12.60
GF Value